- Home
- DTF vs AGEN Comparison
DTF vs AGEN Comparison
Compare DTF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- AGEN
- Stock Information
- Founded
- DTF 1991
- AGEN 1994
- Country
- DTF United States
- AGEN United States
- Employees
- DTF N/A
- AGEN N/A
- Industry
- DTF Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTF Finance
- AGEN Health Care
- Exchange
- DTF Nasdaq
- AGEN Nasdaq
- Market Cap
- DTF 79.8M
- AGEN 87.7M
- IPO Year
- DTF N/A
- AGEN 2000
- Fundamental
- Price
- DTF $11.36
- AGEN $4.26
- Analyst Decision
- DTF
- AGEN Buy
- Analyst Count
- DTF 0
- AGEN 2
- Target Price
- DTF N/A
- AGEN $14.50
- AVG Volume (30 Days)
- DTF 21.1K
- AGEN 439.7K
- Earning Date
- DTF 01-01-0001
- AGEN 08-11-2025
- Dividend Yield
- DTF 3.64%
- AGEN N/A
- EPS Growth
- DTF N/A
- AGEN N/A
- EPS
- DTF 0.44
- AGEN N/A
- Revenue
- DTF N/A
- AGEN $101,706,000.00
- Revenue This Year
- DTF N/A
- AGEN $26.25
- Revenue Next Year
- DTF N/A
- AGEN N/A
- P/E Ratio
- DTF $24.34
- AGEN N/A
- Revenue Growth
- DTF N/A
- AGEN N/A
- 52 Week Low
- DTF $10.29
- AGEN $1.38
- 52 Week High
- DTF $11.19
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- DTF 60.52
- AGEN 39.79
- Support Level
- DTF $11.21
- AGEN $4.12
- Resistance Level
- DTF $11.38
- AGEN $4.37
- Average True Range (ATR)
- DTF 0.07
- AGEN 0.21
- MACD
- DTF 0.00
- AGEN 0.01
- Stochastic Oscillator
- DTF 83.33
- AGEN 26.67
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).